Research peptide blend · Fact sheet
Thymosin alpha-1 + thymulin
Also known as TA1/thymulin blend
Thymosin alpha-1 + thymulin combines thymosin alpha-1 and thymulin. Human evidence for the exact blend is not established; studies of individual ingredients do not validate the mixture.
What is Thymosin alpha-1 + thymulin?
thymosin alpha-1 and thymulin are discussed together under this name. Ratios, salts and formulations can differ between products.
Thymulin is a zinc-dependent hormone; peptide identity and biological activity cannot be inferred from a blend name.
Benefits & claims
Interest centers on immune signaling and thymus-derived peptides.
What the evidence supports
- Thymosin alpha-1 clinical studies do not test the addition of thymulin.
- Thymulin experiments in immune cells and gene-delivery animal models do not establish benefit from an administered peptide blend.
- Immune-marker changes do not establish fewer infections or improved autoimmune outcomes.
Research areas
- Interest centers on immune signaling and thymus-derived peptides.
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for Thymosin alpha-1 + thymulin. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Thymulin is a zinc-dependent hormone; peptide identity and biological activity cannot be inferred from a blend name.
- No published ingredient regimen can be assembled into a supported regimen for this combination.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Human efficacy and adverse-event rates for the exact formulation
- Chemical compatibility, stability and ingredient identity
- Whether combined effects differ from the ingredients alone
Side effects & risks
- FDA describes immunogenicity and characterization concerns for thymosin alpha-1.
- The exact mixture has no established human interaction, autoimmune-disease or long-term safety profile.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Limited or unclear evidenceThe reviewed sources do not establish efficacy or a human regimen for this exact combination. Ingredient-only experiments cannot show that the mixture is effective, synergistic or safer.
Studies
Multicenter randomized study in severe sepsis with important setting and design limits.
In-vitro cytokine experiment using cells from healthy volunteers and people with lupus.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
There is no FDA-approved Thymosin alpha-1 + thymulin product or established approved use for this combination. Ingredient approvals, where present, do not transfer to the blend.
No FDA-approved product for this entry
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Human efficacy and adverse-event rates for the exact formulation
- Chemical compatibility, stability and ingredient identity
- Whether combined effects differ from the ingredients alone
Summary
Immune-marker changes do not establish fewer infections or improved autoimmune outcomes.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedETASS randomized sepsis trial
Multicenter randomized study in severe sepsis with important setting and design limits.
- pubmedThymulin and human immune cells
In-vitro cytokine experiment using cells from healthy volunteers and people with lupus.
- fdaFDA: safety concerns for nominated bulk substances
Ingredient-specific uncertainties; compounding consideration is separate from FDA drug approval.